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Approximately 2 billion people worldwide have evidence of hepatitis 
B virus (HBV) exposure, and an estimated 400 million are chronically 
infected.1 Sub-Saharan Africa has the largest burden of human 
immunodeficiency virus (HIV) infections in the world and is also an 
HBV endemic area. South Africa’s HBV prevalence is estimated to be 
10%; however, this estimate comes from studies that were conducted 
in high-risk groups for HBV such as adult males or children during 
the pre-vaccination era.2  
HBV co-infection with HIV is common, affecting 5 - 10% of 
patients infected with HIV. In developed countries where sexual 
and injection-drug-use exposures account for most HBV and HIV 
infections, the prevalence of chronic HBV infection may be ≥10-fold 
higher than the background prevalence among patients infected with 
HIV in some risk groups.3 Most data from sub-Saharan Africa show 
less than 2-fold or no increase in the prevalence of chronic HBV 
infections in patients infected with HIV,4 with few studies reporting 
more than a 2-fold increase.5,6
The development of an immunosuppressive status such as in organ 
transplantation, cancer and HIV/AIDS might induce reactivation of 
occult HBV with reappearance of the typical serological profile of 
productive infection.7-9 Occult HBV infection refers to the presence 
of HBV DNA without detectable hepatitis B surface antigen (HBsAg) 
with or without hepatitis B core antibodies (anti-HBc) or hepatitis B 
surface antibodies (anti-HBs) outside the pre-seroconversion window 
period.10 The ‘anti-HBc only’ serological pattern is a common marker 
of occult HBV infection. Some South African studies have reported 
a high prevalence of occult HBV infection among patients infected 
with HIV.5,11 
The limitations (e.g. small sample size) and divergent results of the 
few sub-Saharan HBV/HIV co-infection studies demonstrate a need 
for more research in this area.4 We aimed to assess the serological and 
molecular characteristics of HBV in patients with AIDS.
Methods
Study population
This cross-sectional, case-control study was conducted in an urban, 
secondary hospital (Tshwane District Hospital, Pretoria), Gauteng 
province, South Africa. Four hundred South African participants 
(200 patients with AIDS and 200 HIV-negative participants) were 
enrolled from June 2007 to January 2009. AIDS was defined as 
CD4+ cell count of <200 cells/µl in patients infected with HIV. 
All participants were recruited from the same centre, Tshwane 
District Hospital HIV Clinic, which offers both HIV testing and 
antiretrovirals (ARVs), e.g. if tested positive for HIV at a voluntary 
counselling and testing (VCT) section, patients get referred to the 
ARV section of the clinic. HIV-negative participants (control group) 
were identified and recruited after HIV testing, while participants 
with AIDS were recruited from the HIV clinic before starting ARV 
treatment. The minimum age requirement for enrollment was 
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Objective. As sub-Saharan Africa is highly endemic for hepatitis B 
virus (HBV) and human immunodeficiency virus (HIV) infections, 
and their co-infection requires special management, we aimed 
to assess the serological and molecular characteristics of HBV in 
patients with AIDS. 
Design. This was a cross-sectional, case control study, which 
enrolled 200 patients with AIDS and 200 HIV-negative controls. 
HBV serology was done in all participants and HCV serology 
in participants with a hepatitis B core antibody (anti-HBc) only 
serological pattern. Nested HBV polymerase chain reaction (PCR) 
and HBV viral load assays were used for HBV molecular detection.
Results. Hepatitis B surface antigen (HBsAg) prevalence was 
3-fold higher while the ‘anti-HBc only’ pattern was 6-fold higher in 
the AIDS group compared with the controls. Mean HBV viral load 
was significantly higher in HBsAg-positive patients with CD4+ 
cell counts <100 cells/µl than in patients with CD4+ cell counts of 
100-200 cells/µl (p=0.019). There were markedly reduced hepatitis 
B surface antibody (anti-HBs) titres in the AIDS group compared 
with the controls (p=0.002). A significant proportion of AIDS 
patients with an ‘anti-HBc only’ pattern had CD4+ cell counts <100 
cells/µl (p=0.004). Occult HBV prevalence was 3.5% in the AIDS 
group compared with 1% in the controls (p=0.092). When occult 
HBV infection was taken into consideration, the overall HBV 
prevalence became 10% in the AIDS group and 3% in the control 
group. 
Conclusion. We showed an increased HBV prevalence in patients 
with AIDS and identified a CD4+ cell count <100 cells/µl as a 
major risk factor for the ‘anti-HBc only’ pattern and increased 
HBV replication. These data have significant public health 
implications for HBV in developing countries, especially in areas 
where antiretroviral (ARV) guidelines do not cater for HBV/HIV 
co-infection. 
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18 years. Questionnaire forms were used to collect participants’ 
demographic and HBV risk-assessment data. Ethics approval for this 
study was granted by the University of Pretoria, and written informed 
consent was obtained from all participants before enrollment.
Sample collection and laboratory tests
Plasma and serum samples were obtained from all participants. All 
samples were stored at -70ºC within 24 - 72 hours of collection. 
Serological testing was done on serum samples and molecular 
testing on plasma samples. Architect (Abbott Diagnostics, 
Wiesbaden, Germany) and Modular Analytics E170 (Roche 
Diagnostics, Mannheim, Germany) immunoassays, which are 
fourth-generation HIV enzyme-linked immunosorbent assays 
(ELISA), were used for HIV diagnosis. Axsym immunoassays 
(Abbott Diagnostics, Wiesbaden, Germany) were used for HBV 
and hepatitis C virus (HCV) serological testing. The HBV screening 
included HBsAg, anti-HBs and anti-HBc. Hepatitis B e-antigen 
(HBeAg) and hepatitis B e-antibodies (anti-HBe) were done on all 
HBsAg-positive specimens as well as those found to be positive for 
anti-HBc alone during HBV screening. HCV serology was done in 
participants with an ‘anti-HBc only’ serology as HCV infection is 
often associated with this serological picture.12 
Viral nucleic acid was extracted from 100 µl of plasma using 
the MagNa Pure LC Total Nucleic Acid Isolation kit in the MagNa 
Pure LC instrument (Roche Diagnostics, Germany) according to 
manufacturer’s instructions. Nested HBV DNA polymerase chain 
reaction (PCR) assay (qualitative in-house assay) was performed 
to detect occult HBV infections in participants who were HBsAg-
negative after HBV serological screening. HBV core primers were 
used for nested HBV-PCR as previously described.11 The sensitivity 
of the nested HBV-PCR was determined by serial dilution (10-fold 
dilutions: 10-1–10-7) of samples with known HBV viral loads.
HBV viral loads were determined by Cobas TaqMan 48 HBV 
assay (Roche Molecular Systems, Inc., Branchburg, USA) for all 
HBsAg-positive participants, those with ‘anti-HBc only’ pattern and 
in those positive on nested HBV PCR. Epics and UniCel DxC880i 
analysers (Beckman Coulter Diagnostics) were used for CD4 count 
measurements and liver function tests (LFTs), respectively.
Data analysis
Descriptive analysis was used to obtain summary statistics (mean, 
standard deviation, standard error, and 95% confidence intervals) 
for the parameters. This was followed by a comparison between the 
groups using two sample t-test for proportions. The mean HBV viral 
load and anti-HBs measurements between groups were compared 
using the Mann-Whitney or Wilcoxon rank sum test. The software 
used was STATA 11.2. A p-value of <0.05 was considered statistically 
significant. 
Results
Demographics 
Black subjects comprised 98% of participants in this study and there 
were more males in the control group than in the AIDS group. The 
mean age was higher in the AIDS group. Only a small proportion 
of participants were vaccinated (0.5% in the AIDS group v. 3% in 
controls). Intravenous (IV) drug use and the number of lifetime 
sexual partners were significantly higher in the controls and the AIDS 
group, respectively. The mean CD4+ cell count in the AIDS group 
was 92.9 cells/µl (Table 1).
HBV serology results 
HBsAg prevalence of 6.5% in the AIDS group was significantly higher 
than that of 2% in the control group. The total HBV exposure was 
significantly higher in the AIDS group compared with the control 
group, and the same trend was also noticed for both HBeAg and 
‘anti-HBc only’ prevalence (Table 1). When stratifying the HBsAg-
positive AIDS participants by CD4+ cell counts, the group with 
CD4+ cell counts of <100 cells/µl had a higher HBeAg prevalence of 
83.0% (5 of 6) compared with 57.1% (4 of 7) in the group with CD4+ 
cell counts of 100 - 200 cells/µl; however, this difference was not 
statistically significant (p=0.680). HBeAg prevalence was 25% (1 of 
4) in HBsAg-positive participants in the control group (Table 2). Two 
HBsAg-positive patients with AIDS had negative anti-HBc (Table 2). 
The ‘anti-HBc only’ serological pattern was 6-fold higher in the 
AIDS group compared with the control group (Table 1). When 
patients with an ‘anti-HBc only’ serology in the AIDS group were 
stratified according to CD4+ cell counts, 73.7% (14 of 19) had CD4+ 
cell counts of <100 cells/µl compared with 26.3% (5 of 19) in the 
group with CD4+ cell counts of 100 - 200 cells/µl (p=0.004) (Table 3). 
HCV serology results were negative in all patients with an ‘anti-HBc 
only’ pattern (Table 3). 
In the AIDS and control groups 60.5% and 76.0%, respectively, 
had no immunity to HBV (Table 1). AIDS patients had  significantly 
decreased anti-HBs titres; mean titre of 235.17 mIU/ml compared to 
514.29 mIU/ml in the control group (p=0.002). No difference was 
found in mean anti-HBs titres when the AIDS group was stratified 
by CD4+ cell counts. 
HBV viral load results 
The lower detection limit of the HBV viral load assay was 6 IU/
ml (~30 copies/ml). Mean HBV viral loads were significantly 
higher in HBsAg-positive patients with CD4+ cell counts of <100 
cells/µl compared with the group with CD4+ cell counts of 100 - 
200 cells/µl (p=0.019) (Table 2). HBV viral load values >110 000 
000 IU/ml were excluded from the comparison between these 
groups as they are outliers (fall outside the reference range). 
Interestingly, even the HBeAg-negative (but anti-HBe-positive)
patient (3 658) with a CD4+ cell count of <100 cells/µl (Table 
2) had a very high HBV viral load compared with counterparts 
(3 464 and 3 321) with CD4+ cell counts of 100 - 200 cells/µl.  
Nested HBV-PCR results 
Nested HBV-PCR was used for detection of occult HBV infection, and 
its performance was assessed in all HBsAg-positive samples; it was 
positive in all these samples except for one that had a <6 IU/ml viral 
load (with an HBsAg titre of 217.04 S/N) (Table 2). Its lower detection 
limit was 0.2 IU/µl (~1 copy/µl) on serial dilution of HBsAg-positive 
samples with known viral loads (Fig. 1). This high sensitivity of 
nested HBV-PCR was noticed in some samples where HBV viral load 
was <6 IU/ml, but nested PCR was clearly positive (Table 3). Occult 
HBV infection was detected in most participants with ‘anti-HBc only’ 
serological picture (Table 3) and in one participant who was positive 
for both anti-HBc and anti-HBs (confirmed on repeat serology). 
The latter had an anti-HBs titre of 15 mIU/ml, a CD4+ cell count of 
72 cells/µl, positive nested HBV-PCR, HBV viral load of 290 IU/ml, 
and alanine aminotransferase (ALT) of 16 IU/l. In total, occult HBV 
prevalence was 3.5% in the AIDS group compared with 1% in the 
control group (p-value – 0.092). Only one patient with occult HBV 
infection had an HBV viral load of >200 IU/ml (mentioned above). 
Contamination was successfully avoided in the nested PCR runs 
as all negative controls used at the end of each run or in between 
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samples were negative (e.g. Fig. 1). Subsequently, all positive samples 
on nested PCR were sequenced, and the phylogenetic tree also did 
not show any indication of contamination (data not shown). When 
occult HBV infection was taken into consideration, the overall HBV 
prevalence in this study became 10% in the AIDS group and 3% in 
the control group.
Liver function tests
ALT levels were normal or slightly raised in HBsAg-positive patients 
with AIDS (Table 2).
Discussion
This study demonstrates a 3-fold increase in HBsAg prevalence in 
patients with AIDS (6.5%) compared with the control group (2%). This 
impact would have been difficult to observe without using a control 
group, as the average South African HBsAg prevalence is considered 
to be 10%. Therefore, HBV/HIV co-infection studies without a control 
group are more likely to underestimate the impact HIV/AIDS has on 
HBV prevalence, especially in areas of high HBV endemicity where 
most of the population are exposed to HBV during childhood. A study 
in South African patients with AIDS at the Chris Hani Baragwanath 
Hospital noted a similar HBsAg prevalence of 6% but could not 
conclude whether this was high or not, probably because of the lack of 
a control group.13 The reason for low HBV prevalence (<10%) in both 
groups of this study could be that the HBsAg prevalence of 10% comes 
from studies conducted in populations at high risk for chronic HBV 
(adult males or children only) and, therefore, is not always applicable 
for assessment of HBV prevalence in the general adult population. For 
instance, Tsebe et al.14 noticed a 3.3% HBsAg prevalence in the general 
adult population of Limpopo (formerly Northern Province). Despite 
the number of lifetime sexual partners being significantly higher in 
the AIDS group, this is unlikely to have influenced the high HBV 
prevalence in this group as other HBV risk factors such as male gender 
and IV drug use were significantly higher in the controls.  
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Table 1. Demographics and HBV serology data
AIDS group Control group
(n=200) (n=200) p-values
Demographics
Mean age (range) 37 (22-75) 31 (18-71) 0.000
Mean CD4 count (range) 92.9 (1-199) ND N/A
Gender
Males 36.0% (72) 52.5% (105) 0.001
Females 64.0% (128) 47.5% (95) 0.001
Race
Blacks 99.5% (199) 97.0% (194) 0.057
Whites 0.5% (1) 3.0% (6) 0.057
Intravenous drug use* 0.0% (0 in 200) 4.6% (9 in 197) 0.002
MSM * 4.3% (3 in 70) 1.0% (1 in 104) 0.548
Lifetime sexual partners*
<5 46.2% (73) 57.5% (92) 0.044
≥5 53.8% (85) 42.5% (68) 0.044
Residence within the first 5 years 
of life*
Rural 65.3% (130) 68.0% (134) 0.569
Urban 34.7% (69) 32.0% (63) 0.569
HBV vaccination 0.5% 3.0% 0.057
HBV serology
HBsAg 6.5% (13) 2% (4) 0.026
HBeAg 4.5% (9) 0.5% (1) 0.010
Anti-HBc only 9.5% (19) 1.5% (3) 0.000
Anti-HBs only 3% (6) 2.5% (5) 0.760
Anti-HBs + anti-HBc 18.5% (37) 17% (34) 0.695
Anti-HBc + anti-HBe 2% (4) 1% (2) 0.411
Negative HBV markers 60.5% (121) 76% (152) 0.001
Total HBV exposure 36.5% (73) 21.5% (43) 0.001
*Some data were not gathered for all participants because of the sensitive nature of some questions or missed questions during completion of the questionnaire, and percentage calculation was only 
done for those who answered these questions.
N/A = not applicable; ND = not done; MSM = men who have sex with men; HBV = hepatitis B virus; HBsAg = hepatitis B surface antigen; HBeAg = HBV e antigen; anti-HBc = hepatitis B core 
antibody; anti-HBs = hepatitis B surface antibody.
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HBV prevalence varies considerably in South Africa owing 
to gender, age, race and geographic location of a studied 
population, e.g. blacks, males, and residence in the rural or 
coastal areas such as Eastern Cape and KwaZulu-Natal (KZN) 
are risk factors associated with high HBV prevalence. This 
prevalence could be as high as 10% or more in those at high 
risk for HBV and as low as 1% in low risk groups as noted in 
children born into an urban environment.2 There was a lower 
HBV prevalence in the control group despite more risk factors 
for chronic HBV prevalence such as higher number of males 
and IV drug users (Table 1).  South African studies have also 
shown an increased HBV prevalence in adult patients infected 
with HIV;5,6 one reported a 22.9% and the other a 5% HBsAg 
prevalence. However, the latter study used an HBsAg prevalence 
of 1% as a reference point even though this prevalence rate 
was only noticed among a group of children born in an urban 
area, and would therefore be inappropriate for a diverse adult 
population in terms of risk factors for HBV.  
Mean HBV viral load of HBsAg-positive patients was 
significantly higher in the AIDS group with CD4+ cell counts 
of <100 cells/µl, indicating an increased HBV replication 
with profound immunosuppression. This in turn results in an 
increased risk of HBV transmission to patients’ close contacts 
(e.g. family members and friends) and susceptible health care 
workers. Immunosuppression could also account for a very 
high HBV viral load in an HBeAg-negative (but anti-HBe-
positive) patient with a CD4+ cell count of <100 cells/µl,15 and 
for failure of some HBsAg-positive patients to produce anti-
HBc (Table 2).16 The undetectable HBV DNA in an HBsAg-
positive participant in the control group was surprising; 
however, this phenomenon has been described in chronic HBV 
infection especially after HBeAg seroclearance.17 
Liver damage is mediated by cytotoxic immune responses in 
immunocompetent individuals. However, HBV/HIV co-infected 
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Table 2. Characteristics of HBsAg-positive individuals in the AIDS group v. control group
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Pt ID = participant identity; HBsAg = hepatitis B surface antigen; anti-HBs = hepatitis B surface antibody; anti-HBc = hepatitis B core antibody; HBeAg = hepatitis B virus e antigen; anti-HBe = 
antibody to HBVe antigen; ALT = alanine aminotransferase; HBV-PCR = HBV polymerase chain reaction; F = female; M = male; ND = not done.
Fig. 1. Serial dilution of a sample that had an HBV viral load of 33839.3 IU/
µl. Nuclease-free water served as a template for negative controls (NC) used 
between dilutions. Analysis of nested HBV-DNA PCR products was done on 
2% agarose gel electrophoresis. Molecular weight (MW) marker = 100 bp 
DNA marker.
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patients are often asymptomatic and usually have normal or slightly 
raised ALT levels (Table 2), possibly because of weak cytotoxic 
immune responses as a result of immunosuppression. Paradoxically, 
the risk of developing cirrhosis is much greater in HBV/HIV 
co-infected patients despite having less necro-inflammatory activity 
in the liver. HBV replication in the liver is non-cytopathic; however, 
fibrosing cholestatic hepatitis, a severe and rapidly progressive form 
of HBV infection thought to be due to a direct cytopathic effect 
of the virus, has been anecdotally described in patients infected 
with HIV and other groups of immunosuppressed patients.18 HBV/
HIV co-infected patients with AIDS are also at a high risk of 
developing immune reconstitution inflammatory syndrome (IRIS) 
after initiation of highly active antiretroviral therapy (HAART). The 
accelerated HBV progression (Table 2) and higher likelihood of IRIS 
in patients with AIDS clearly argue for earlier initiation of HAART in 
HBV co-infected patients before their CD4+ cell counts drop below 
200 cells/µl as advocated by the 2010 WHO ARV guidelines.19 
HBV/HIV co-infection requires special management as some ARV 
drugs (tenofovir, lamivudine and emtricitabine) are active against 
HBV. Dual therapy for HBV is recommended in HIV co-infected 
patients in order to avoid HBV drug resistance, particularly to 
lamivudine, which has a low resistance barrier. As a result, the use of 
tenofovir and lamivudine/emtricitabine is recommended as part of a 
HAART regimen for HBV/HIV co-infected patients.20 
Isolated anti-HBc is commonly associated with occult HBV 
infection. Mphahlele et al.11 reported an occult HBV prevalence of 
33.3% in South Africans infected with HIV who had an ‘anti-HBc 
only’ serological picture. In our study, there was a significantly high 
proportion of patients with an ‘anti-HBc only’ serological picture in 
the AIDS group, and occult HBV infection was detected in 31.6% 
of these patients. The finding of positive nested HBV PCR in some 
samples with HBV viral load <6 IU/ml shows that a more sensitive 
test is needed for the diagnosis of occult HBV (Table 3).  Other South 
African studies have also reported a high prevalence of occult HBV 
in patients with AIDS.5,6,11 The finding of negative HCV serology 
in all patients with an ‘anti-HBc only’ serological picture was not 
surprising, given that South Africa has an HCV prevalence of less 
than 2%.21 
Although there is uncertainty regarding the clinical significance of 
occult HBV infection, a clear association of occult HBV infection and 
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Table 3. Characteristics of patients with ‘anti-HBc only’ serological pattern in the AIDS group versus control group
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Pt ID = participant identity; ALT = alanine aminotransferase; HCV = hepatitis C virus; HBV = hepatitis B virus; HBV-PCR = HBV polymerase chain reaction; F = female, M = male; ND = not 
done; TND = target not detected;*Insufficient sample.
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liver disease in the absence of other causes such as HCV infection or 
alcohol abuse has been described.10 The prevalence of occult HBV 
ranges from 0% to 10% among individuals without liver disease, 11% 
to 19% in patients with chronic hepatitis, 12% to 61% in patients 
with hepatocellular carcinoma, and 1% to 95% in patients with HCV 
infection.22 It would be difficult to diagnose occult HBV infection 
in patients with AIDS as some guidelines utilise only HBsAg for 
HBV screening.19,23 More data are needed on occult HBV infection 
to elucidate its role in clinical disease in HIV co-infected patients, 
especially in areas of high HBV endemicity.
Markedly reduced anti-HBs titres could explain the high HBsAg 
prevalence and ‘anti-HBc only’ presentation in patients with AIDS, as 
some of these individuals eventually lose protective antibodies. This 
loss of HBV protective immunity may lead to reactivation of HBV, or 
exposure to new HBV infections. As patients infected with HIV lose 
protective antibody levels more quickly (40% loss in 1 year vs 5% loss in 
HIV-negative individuals),24,25 it may be a good practice to administer 
HBV vaccine booster doses to those with relatively low anti-HBs titres 
prior to commencement of HAART. Some experts use anti-HBs levels 
of less than 100 IU/l as a cut-off point for HBV vaccine booster doses 
in HIV-infected individuals,26 and our findings support this practice 
and reinforce its value in HIV endemic countries. The lack of HBV 
immunity in 60.5% of patients with AIDS could be explained by the 
fact that HBV vaccine was only implemented in the South African 
Expanded Programme on Immunisation (EPI) in 1995 and then not 
routinely offered to adults. Patients infected with HIV but with no 
HBV immunity should be considered for HBV vaccination to prevent 
HBV co-infection. Hepatitis B vaccine response in patients infected 
with HIV correlates with the CD4+ cell counts (87%, 33% and 25% in 
CD4 count >500, 200 - 500 and <200 cells/µl, respectively).24 Therefore, 
HBV vaccination of patients infected with HIV may be most cost-
effective in patients with CD4 count >500 cells/µl. In addition to using 
HBsAg in the HBV screening protocol, HIV management guidelines 
for developing countries should also incorporate anti-HBs to identify 
patients with low or no HBV immunity.
HIV/AIDS increased HBV prevalence and has enhanced 
other transmission risk patterns for HBV, which were previously 
uncommon in sub-Saharan Africa. For instance, horizontal 
transmission in childhood predominates in this region, but, with 
high HBV viral loads in HIV co-infected patients, there is now a 
high risk for both horizontal transmission among adults and vertical 
transmission of HBV. This undermines the HBV vaccination efforts 
which are targeted at reducing the HBV prevalence, and warrants 
changes in HBV screening and vaccination policies in sub-Saharan 
Africa in order to curb the spread of HBV. For example, in the 
past HBV screening of pregnant South African women was not 
considered to be cost-effective as HBV mono-infected carriers 
in South Africa are usually HBeAg-negative and therefore less 
infectious.27 This practice may need to be changed for HIV/HBV 
co-infected patients with AIDS as they tend to be HBeAg-positive 
with high HBV viral loads.
Conclusions
This study demonstrated a significantly increased HBV prevalence 
and decreased anti-HBs titres in patients with AIDS, and also 
identified a CD4+ cell count of <100 cells/µl as a major risk factor for 
the ‘anti-HBc only’ serological pattern and increased HBV replication. 
There was an increased prevalence of occult HBV infection in 
patients with AIDS. These findings have important diagnostic and 
treatment implications for HBV in patients with AIDS, especially in 
areas with a high burden of HIV and HBV infections. Therefore, a 
more comprehensive HBV screening programme is recommended 
for adequate management of HBV in HIV/AIDS. This should include 
HBsAg and anti-HBs, to identify HBsAg-positive individuals and 
also those with no HBV immunity or low anti-HBs titres. Although 
this comprehensive HBV screening has cost implications, it could 
be cost-effective even in resource-constrained settings when HBV 
vaccine is made available for prevention of HBV in patients infected 
with HIV. Early initiation of HAART should be considered in HBV/
HIV co-infection to avoid HBV disease progression and IRIS, which 
are more likely to occur at low CD4+ cell counts.
The limitations of this study include the small sample size, and the 
inability to exclude other factors associated with isolated anti-HBc 
such as the ‘HBsAg window period’ of acute HBV infection.
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